The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2024 | How does selinexor fit into the treatment algorithm for myeloma?
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the optimal use of selinexor, highlighting its effectiveness when combined with bortezomib and dexamethasone (the SVd regimen) as a second-line treatment for patients who are refractory to both lenalidomide and anti-CD38 antibodies. Dr Zamagni notes that this combination offers a unique therapeutic approach with dual mechanisms of action, providing a promising balance between efficacy and toxicity in this challenging patient group. Although selinexor can also be used in later lines of treatment as monotherapy or combined with dexamethasone, the clinical outcomes in this setting are less encouraging. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
